Business
Propanc Biopharma’s CEO to Present at Sidoti & Company Micro-Cap Virtual Investor Conference
Wednesday & Thursday, November 9 – 10, 2022 MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a
About this update from Propanc Biopharma, Inc.
[{"type":"text","content":"\nWednesday & Thursday, November 9 – 10, 2022\n\n MELBOURNE, Australia--(BUSINESS WIRE)--\nPropanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that Mr. James Nathanielsz, Propanc’s Chief Executive Officer and Co-Founder, will conduct investor meetings and present at the upcoming Sidoti & Company’s upcoming Micro-Cap Virtual Investor Conference, which will be held on Wednesday and Thursday, November 9 – 10, 2022.\n\nMr. Nathanielsz will deliver his corporate presentation on Wednesday, November 9, at 4:00pm, Eastern Standard Time.\n\nThe Sidoti & Company Micro-Cap Investor Conference is a virtual event featuring dynamic, micro-cap companies interacting with a number of institutional investors from across the United States. Sidoti & Company is a provider of independent securities research focused on small and micro-cap companies and the institutions that invest in their securities. Their investor conferences have emerged as a leading forum for interaction between issuers and investors in the small and micro-cap investment community.\n\n“The demand for innovative healthcare companies by institutional investors to present at the upcoming Sidoti & Company Micro-Cap Conference led to an exciting opportunity for Propanc to present the latest developments of our lead product candidate, PRP, as we advance towards a First-In-Human study in advanced cancer patients suffering from solid tumors,” said Mr. Nathanielsz. “I look forward to demonstrating how PRP treats and prevents metastatic cancer by targeting and eradicating cancer stem cells, free from side effects associated with standard treatment approaches. Furthermore, we recently announced potential future clinical applications in conjunction with our joint research partners, where PRP alters the tumor microenvironment. This means pre-treating tumors which are chemo-resistant so that they are susceptible to standard therapies once again.”\n\nPRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include kidney, ovarian, breast, brain, prostate, colorectal, lung, liver, uterine and skin ...